Mealtime glucose regulation with nateglinide in healthy volunteers: Comparison with repaglinide and placedo

Diabetes Care

Volumn 24, Issue 1, 2001, Pages 73-77

  Manjarrez, Gabriel ^a   Herrera, Rocio ^a   Leon, Monica ^a   Hernandez R, Jorge ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; NATEGLINIDE; PLACEBO; REPAGLINIDE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; PHARMACODYNAMICS;

EID: 0035132993     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.1.73     Document Type: Article

References (20)

1. New non-sulfonylurea insulin secretagogues
2. Possibility of ideal blood glucose control by a new oral hypoglycemic agent N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals
3. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent (-)-N-(trans-4-isopropylcyclohexane-carbonyl)-D-phenylalanine (A-4166)
4. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects
5. Comparative effects of A-4166, sulfonylureas and repaglinide on meal induced glucose excursions in normal rats
6. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycemic agents, NN623 and A4166
7. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: Comparison with voglibose and glibenclamide
8. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
9. Synergistic effects of nateglinide and meal administration in patients with type 2 diabetes
10. Focus on repaglinide: An oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas
11. ATP channel activity and membrane binding studies with nateglinide: A comparison with sulfonylureas and repaglinide
12. Pharmacodynamics of nateglinide and repaglinide in cynomolgus monkeys
13. The pharmacokinetics and pharmacodynamics of nateglinide in relation to meal timing in non-insulin dependent diabetes mellitus (NIDDM) subjects
14. Quantitation of the new hypoglycemic agent AG-EE 388ZW in human plasma by automated high performance liquid chromatography with electrochemical detection
15. Nonfasting plasma glucose is a better marker of diabetic control in type 2 diabetes
16. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
17. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients
18. How does glibenclamide lower plasma glucose concentration in patients with type 2 diabetes?
19. Glipizide versus tolbutamide, an open trail
20. Nateglinide increases first phase insulin secretion and enhances glucose clearance in type 2 diabetes